Neoadjuvant TherapyChemoradiotherapy, AdjuvantChemoradiotherapyEsophagectomyRectal NeoplasmsRadiotherapy, AdjuvantEsophageal NeoplasmsChemotherapy, AdjuvantCombined Modality TherapyTreatment OutcomeFluorouracilNeoplasm StagingAdenocarcinomaCarcinoma, Squamous CellDisease-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesSurvival RatePrognosisNeoplasm Recurrence, LocalSurvival AnalysisKaplan-Meier EstimateCisplatinRadiotherapy DosageHead and Neck NeoplasmsTaxoidsRadiotherapyDeoxycytidineAntineoplastic AgentsFollow-Up StudiesBreast NeoplasmsDose FractionationNasopharyngeal NeoplasmsPaclitaxelAntimetabolites, AntineoplasticInduction ChemotherapyPreoperative CarePositron-Emission TomographyCarboplatinProspective StudiesOutcome Assessment (Health Care)DoxorubicinEpirubicinLung NeoplasmsDrug Administration ScheduleFluorodeoxyglucose F18Radiotherapy, ConformalTime FactorsDigestive System Surgical ProceduresOrganoplatinum CompoundsHypopharyngeal NeoplasmsRemission InductionLymphatic MetastasisCystectomyOrgan Sparing TreatmentsEsophagogastric JunctionLeucovorinCyclophosphamidePredictive Value of TestsCarcinoma, Non-Small-Cell LungMuscle NeoplasmsPancreatic NeoplasmsBrachytherapyLaryngeal NeoplasmsNeoplasm, ResidualUterine Cervical NeoplasmsDeglutition DisordersRadiation InjuriesFeasibility StudiesLymph Node ExcisionTomography, X-Ray ComputedTumor Markers, BiologicalRandomized Controlled Trials as TopicRadiopharmaceuticalsMultivariate AnalysisGastrectomyRadiotherapy, Intensity-ModulatedPregnancy OutcomeAnthracyclinesCarcinomaOropharyngeal NeoplasmsVinblastineAntibodies, Monoclonal, HumanizedMucositisRadiation-Sensitizing AgentsProportional Hazards ModelsMultimodal ImagingOxonic AcidClinical Trials, Phase II as TopicReceptor, erbB-2TegafurStomach NeoplasmsHydroxyureaRisk AssessmentRisk FactorsUrinary Bladder NeoplasmsAnus NeoplasmsIfosfamideNeoplasm InvasivenessClinical Trials as Topic